<PAGE>
HOGAN & HARTSON
L.L.P.
ALAN L. DYE COLUMBIA SQUARE
PARTNER 555 THIRTEENTH STREET, N.W.
DIRECT DIAL (202) 637-5737 WASHINGTON, DC 20004-1109
INTERNET [email protected] TEL. (202) 637-5600
FAX (202) 637-5910
January 5, 1998
BY HAND
Shelley E. Parratt
Assistant Director
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: Osiris Therapeutics, Inc.
Registration Statement on Form S-1
Filed July 17, 1997
Commission File No. 333-31435
Dear Ms. Parratt:
Enclosed is an application for the withdrawal of the above-referenced
registration statement (the "Registration Statement"). We assume that the Form
8-A filed by Osiris on Novemer 24, 1997 also will be deemed withdrawn, given
that, by virtue of Rule 12b-6 under the Securities Exchange Act of 1934, the
withdrawal of the Registration Statement means that the Form 8-A cannot become
effective.
Enclosed separately is a request to withdraw the related confidential
treatment request submitted pursuant to Rule 406 under the Securities Act of
1933.
<PAGE>
HOGAN & HARTSON L.L.P.
Securities and Exchange Commission
January 5, 1998
Page 2
Please call me if you have any questions regarding the enclosed materials.
Sincerely,
/s/ Alan L. Dye
Alan L. Dye
Attachment
cc: James S. Burns
Osiris Therapeutics, Inc.
M. Kathleen Haller
Amy Meltzer Starr
Securities and Exchange Commission
Jeffrey W. Preusse
The Nasdaq Stock Market, Inc.
